These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16763521)

  • 1. HIV-1 reverse transcriptase mutants resistant to nonnucleoside reverse transcriptase inhibitors do not adversely affect DNA synthesis: pre-steady-state and steady-state kinetic studies.
    Domaoal RA; Bambara RA; Demeter LM
    J Acquir Immune Defic Syndr; 2006 Aug; 42(4):405-11. PubMed ID: 16763521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.
    Wang J; Bambara RA; Demeter LM; Dykes C
    J Virol; 2010 Sep; 84(18):9377-89. PubMed ID: 20592075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.
    Gerondelis P; Archer RH; Palaniappan C; Reichman RC; Fay PJ; Bambara RA; Demeter LM
    J Virol; 1999 Jul; 73(7):5803-13. PubMed ID: 10364332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.
    Archer RH; Dykes C; Gerondelis P; Lloyd A; Fay P; Reichman RC; Bambara RA; Demeter LM
    J Virol; 2000 Sep; 74(18):8390-401. PubMed ID: 10954539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency.
    Wang J; Dykes C; Domaoal RA; Koval CE; Bambara RA; Demeter LM
    Virology; 2006 May; 348(2):462-74. PubMed ID: 16504235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
    Kerr SG; Anderson KS
    Biochemistry; 1997 Nov; 36(46):14064-70. PubMed ID: 9369478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.
    Wang J; Li D; Bambara RA; Yang H; Dykes C
    J Gen Virol; 2013 Jul; 94(Pt 7):1597-1607. PubMed ID: 23535575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
    Dykes C; Fox K; Lloyd A; Chiulli M; Morse E; Demeter LM
    Virology; 2001 Jul; 285(2):193-203. PubMed ID: 11437654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
    Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
    J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
    Nikolenko GN; Delviks-Frankenberry KA; Pathak VK
    J Virol; 2010 May; 84(10):5238-49. PubMed ID: 20219933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.
    Ceccherini-Silberstein F; Svicher V; Sing T; Artese A; Santoro MM; Forbici F; Bertoli A; Alcaro S; Palamara G; d'Arminio Monforte A; Balzarini J; Antinori A; Lengauer T; Perno CF
    J Virol; 2007 Oct; 81(20):11507-19. PubMed ID: 17686836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases.
    Esposito F; Kharlamova T; Distinto S; Zinzula L; Cheng YC; Dutschman G; Floris G; Markt P; Corona A; Tramontano E
    FEBS J; 2011 May; 278(9):1444-57. PubMed ID: 21348941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.
    Barnard JP; Huber KD; Sluis-Cremer N
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action.
    Jochmans D; Deval J; Kesteleyn B; Van Marck H; Bettens E; De Baere I; Dehertogh P; Ivens T; Van Ginderen M; Van Schoubroeck B; Ehteshami M; Wigerinck P; Götte M; Hertogs K
    J Virol; 2006 Dec; 80(24):12283-92. PubMed ID: 17020946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic analysis of four HIV-1 reverse transcriptase enzymes mutated in the primer grip region of p66. Implications for DNA synthesis and dimerization.
    Wöhrl BM; Krebs R; Thrall SH; Le Grice SF; Scheidig AJ; Goody RS
    J Biol Chem; 1997 Jul; 272(28):17581-7. PubMed ID: 9211905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis.
    Betancor G; Álvarez M; Marcelli B; Andrés C; Martínez MA; Menéndez-Arias L
    Nucleic Acids Res; 2015 Feb; 43(4):2259-70. PubMed ID: 25662223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA dependent DNA replication fidelity of HIV-1 reverse transcriptase: evidence of discrimination between DNA and RNA substrates.
    Kerr SG; Anderson KS
    Biochemistry; 1997 Nov; 36(46):14056-63. PubMed ID: 9369477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.
    Pham HT; Mesplède T; Wainberg MA
    Retrovirology; 2016 Apr; 13(1):31. PubMed ID: 27130466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.